Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 2;68(5):e0172723.
doi: 10.1128/aac.01727-23. Epub 2024 Apr 8.

Influenza C virus susceptibility to antivirals with different mechanisms of action

Anton Chesnokov  1 , Andrei A Ivashchenko  2 , Yoko Matsuzaki  3 , Emi Takashita  4 , Vasiliy P Mishin  1 , Alexandre V Ivachtchenko  2   5 , Larisa V Gubareva  1
Affiliations

Influenza C virus susceptibility to antivirals with different mechanisms of action

Anton Chesnokov et al. Antimicrob Agents Chemother. .

Abstract

Antiviral susceptibility of influenza viruses was assessed using a high-content imaging-based neutralization test. Cap-dependent endonuclease inhibitors, baloxavir and AV5116, were superior to AV5115 against type A viruses, and AV5116 was most effective against PA mutants tested. However, these three inhibitors displayed comparable activity (EC50 8-22 nM) against type C viruses from six lineages. Banana lectin and a monoclonal antibody, YA3, targeting the hemagglutinin-esterase protein effectively neutralized some, but not all, type C viruses.

Keywords: baloxavir; cap-dependent endonuclease inhibitors; drug susceptibility; lectin; polymerase.

PubMed Disclaimer

Conflict of interest statement

Andrei A. Ivashchenko and Alexandre V. Ivachtchenko are the cofounders of ChemDiv, managing members of AVISA LCC. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig 1
Fig 1
Inhibition of influenza A, B, and C replication by CENIs. EC50, 50% effective concentration; nM, nanomolar. Horizontal lines indicate median EC50; median value displayed above each line. Tested viruses have no PA mutations known to confer reduced susceptibility to baloxavir (acid).
See this image and copyright information in PMC

References

    1. Daniels RS, Tse H, Ermetal B, Xiang Z, Jackson DJ, Guntoro J, Nicod J, Stewart A, Cross KJ, Hussain S, McCauley JW, Lo J. 2020. Molecular characterization of influenza C viruses from outbreaks in Hong Kong SAR, China. J Virol 94:e01051-20. doi:10.1128/JVI.01051-20 - DOI - PMC - PubMed
    1. Sreenivasan CC, Sheng Z, Wang D, Li F. 2021. Host range, biology, and species specificity of seven-segmented influenza viruses-A comparative review on Influenza C and D. Pathogens 10:1583. doi:10.3390/pathogens10121583 - DOI - PMC - PubMed
    1. Jones JC, Yen H-L, Adams P, Armstrong K, Govorkova EA. 2023. Influenza antivirals and their role in pandemic preparedness. Antiviral Res 210:105499. doi:10.1016/j.antiviral.2022.105499 - DOI - PMC - PubMed
    1. O’Callaghan RJ, Loughlin M, Labat DD, Howe C. 1977. Properties of influenza C virus grown in cell culture. J Virol 24:875–882. doi:10.1128/JVI.24.3.875-882.1977 - DOI - PMC - PubMed
    1. DuBois RM, Slavish PJ, Baughman BM, Yun MK, Bao J, Webby RJ, Webb TR, White SW. 2012. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog 8:e1002830. doi:10.1371/journal.ppat.1002830 - DOI - PMC - PubMed

Publication types

LinkOut - more resources